Research Article

CD11b Expression in Acute Myeloid Leukemia is Associated With Hemostatic Complications and Response to Treatment


  • Mehmet BAYSAL
  • Elif G. ÜMİT
  • Gökhan ÖZTÜRK
  • Volkan BAŞ
  • Ahmet Muzaffer DEMİR

Received Date: 07.08.2019 Accepted Date: 25.02.2020 Namik Kemal Med J 2020;8(1):16-21


In our study, we aimed to investigate the effects of CD11b expression on myeloblasts on clinical course and prognosis in patients with AML.

Materials and Methods:

Data of 123 patients diagnosed with AML between 2014-2017 in Trakya University Faculty of Medicine, Department of Hematology, a tertiary referral hospital in the Trakya Region, were evaluated in a retrospective manner. The diagnosis of AML was based on WHO 2016 criteria of Myeloid Neoplasms.


Of the 123 patients in our study, 60 were female, and 63 were male. The mean age was 57.93 years. CD11b positivity was observed in 40 patients. Platelet counts were significantly lower in patients with CD11b positivity (p = 0.004). Likewise, D-dimer levels at presentation were higher in the CD11b positive patient group (p = 0.000). Regarding outcomes, patients with CD11b positivity were found to have lower rates of remission with first-line remission induction therapy (p = 0.003). There was no significant relationship between CD11b positivity and overall survival with Kaplan Meier survival analysis (8.5 months in CD 11b positive group, 12.1 months in negative group, p: 0.436).


Our study demonstrated that patients with CD11b expression had lower remission rates with remission induction chemotherapy.

Keywords: Acute myeloid leukemia, CD11b, flow cytometry, adhesion molecules, hemostasis